Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 1/20 | 0.47 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.47 |
| ▸ | MAOB | P27338 | 9/20 | 0.44 |
| ▸ | MAOA | P21397 | 2/20 | 0.43 |
| ▸ | MRGPRX4 | Q96LA9 | 2/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.40 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.40 |
| ▸ | IDO1 | P14902 | 1/20 | 0.40 |
| ▸ | AGXT | P21549 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11949601 | 0.83 | EGFR (0.49) | EGFRERBB2MAOBMAOAMRGPRX4 | |
| SCHEMBL6960989 | 0.82 | EGFR (0.52) | EGFRERBB2MAOBMAOAMAPT | |
| SCHEMBL13900992 | 0.81 | EGFR (0.53) | EGFRERBB2MAOBMRGPRX4 | |
| SCHEMBL4028363 | 0.81 | MAOB (0.57) | EGFRERBB2MAOBMAOACYP1A2 | |
| SCHEMBL15701549 | 0.80 | EGFR (0.47) | EGFRERBB2MAOBMAOAMRGPRX4 | |
| SCHEMBL24726468 | 0.79 | MAOB (0.48) | MAOBMRGPRX4IDO1AGXTLMNA | |
| SCHEMBL24726471 | 0.76 | MAOB (0.69) | MAOBMAOAMRGPRX4FFAR1 | |
| SCHEMBL18253179 | 0.74 | MAOB (0.66) | MAOBMAOAMRGPRX4 | |
| SCHEMBL14200028 | 0.72 | MAOB (0.56) | MAOB | |
| SCHEMBL20004351 | 0.71 | IDO1 (0.50) | MAOBMAOAMRGPRX4IDO1AGXT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160031860-A1 | ALKYNE SUBSTITUTED QUINAZOLINE COMPOUND AND METHODS OF USE | NEWGEN THERAPEUTICS INC (US) | 2016-02-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160031860-A1 | ALKYNE SUBSTITUTED QUINAZOLINE COMPOUND AND METHODS OF USE | ERBB2, ERBB4, ERBB3 | EGFR 5/4885ERBB2 1/4885MAOB 2081/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.